spacer
home > events calendar > more about event
PHARMACEUTICAL INDUSTRY EVENTS CALENDAR

5th Biennial Biosimilars & Biobetters Congress 2018

Oxford Global - 5th Biennial Biosimilars & Biobetters Congress

16-17 April 2018
Novotel London West Hotel, Hammersmith, London

Oxford Global are proud to present our highly anticipated 5thBiennial Biosimilars & Biobetters Congress, 16th – 17thApril 2018, London, UK. Over 450 proteins, peptides and biosimilars delegates representing leading biotech companies, global pharmaceutical organisations and internationally renowned academic institutions will enjoy over 20 presentations and case studies focusing on the key areas of the biosimilars industry including market access strategies, clinical development, commercialisation, manufacturing and bio-analytics

Oxford Global are proud to present our highly anticipated 5th Biennial Biosimilars & Biobetters Congress, 16th – 17th April 2018, London, UK. Over 450 proteins, peptides and biosimilars delegates representing leading biotech companies, global pharmaceutical organisations and internationally renowned academic institutions will enjoy over 20 presentations and case studies focusing on the key areas of the biosimilars industry including market access strategies, clinical development, commercialisation, manufacturing and bio-analytics

Two-day interactive conference addressing the following topics:

  • Market Access Strategies, Opportunities, Clinical Development and Commercial Challenges
  • Developing Biosimilars and Biobetters – Manufacturing and Bio-analytics 

14 pre-scheduled one to one meetings, exhibition and informal networking opportunities

Co-located with the 11th Annual Proteins & Antibodies Congress and the 5th Annual Peptides Congress

View the Agenda here:

http://bit.ly/2mwfjVU

Free Pre-Congress Live Webinars

Biosimilars: Everyday Practice, Manufacturing Pre-Clinical Trials
Wednesday 7th February 2018 | 10am GMT
Katalin Egyed, EGIS Pharmaceuticals & Rafał Derlacz, Polpharma

Register today for free:

http://bit.ly/2xNJGbG

Biosimilars: The Cancer Patient Perspective

Tuesday 13th February 2018 | 10am GMT

Lydia Makarof, European Cancer Patient Coalition

Register today for free:

http://bit.ly/2j1vAAf 

Can’t make the dates? Still register and a copy of the webinar recording will be sent to you.

For further information, prices & discounts please contact a.fernandez@oxfordglobal.co.uk

phone +44 (0)1865 248455
email info@oxfordglobal.co.uk
web bit.ly/2yHbU87
email Oxford Global Ltd, Part 1st Floor, Godstow Court, Minns Business Park, Botley, Oxford, OX2 0JB
 
Print this page
Send to a friend
   
spacer
Industry Events

14th Annual Biomarkers & Immuno-Oncology World Congress

11-13 June 2018, Westin Boston Waterfront, Boston, Massachusetts

The Biomarkers and Immuno-Oncology World Congress brings together a unique and international mix of large and medium pharmaceutical, biotech and diagnostics companies, leading universities and clinical research institutions, government and national labs, CROs, emerging companies and tool providers—making the Congress a perfect meeting-place to share experience, foster collaborations across industry and academia, and evaluate emerging technologies.
More info >>

Banner of Clinical_Trial_New_England_events_95 on Samedan

Banner of BIO_Europe_Events_102 on Samedan
White Papers

Future-proofing serialization solutions: the importance of strong level 3 capabilities

Adents

The complexities surrounding product serialization for pharmaceutical and medical device companies are immense. While current serialization requirements are limited to marking the unit of sale with a unique data carrier, by 2023 the process will require a product to be traceable through the entirety of its journey - from the individual package through the carton/pallet to its final point of distribution. In the United States, the Healthcare Distribution Management Association (HDMA) is suggesting that pharmaceutical companies begin to support this level of serialization, called aggregation, now. Around the world – in Europe and Asia in particular – disparate track and trace practices are incrementally moving toward a global standard that will, undoubtedly, be more stringent than today’s differing benchmarks. How can companies manage this transformation with the greatest degree of success while also minimizing business disruption? The key to creating an optimal implementation strategy is to select a serialization solution that has strong capabilities at all levels of technology. It’s also important to choose a solution that enables multi-phase implementation
More info >>


News and Press Releases

Charles River Laboratories Makes Investments in High-Throughput Screening Infrastructure

WILMINGTON, Mass.--(BUSINESS WIRE)--Feb. 1, 2018-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced a new agreement which grants Charles River commercial access to AstraZeneca’s (NYSE: AZN) high-throughput screening (HTS) and compound management infrastructure. Through the agreement, Charles River will perform HTS programs for its clients utilizing AstraZeneca’s state-of-the-art HTS facility.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement